These results demonstrated that the PC7A nanovaccine initiates CXCL9 upregulation in a STING-dependent manner, but STING agonist (cGAMP) alone cannot support a sustained increase in CXCL9 and tumor-specific T cells without efficient antigen presentation, and both are required to establish the feedback loop of myeloid cell/CXCL9-CD8+ T/IFNγ in tumors. The gene discussed is IFNG; the disease is neoplasm.